Aims-To determine the cost and sensitivity of sputum cytology in routine use and to determine when sputum cytology is most appropriate. Methods-A retrospective study, based on all sputum cytology requests received in five histopathology/cytopathology laboratories in Yorkshire from 1 January to 31 December 1993. Cytology findings were correlated with histological diagnosis or clinical outcome, and related to the speciality of the referring clinician. Results-Laboratory practice and performance was similar in all five centres. The average laboratory cost of sputum cytology was £26.93. The mean absolute sensitivity was 36% and the specificity was 99.6%. The majority of specimens was submitted by general physicians or geriatricians. The largest proportion of positive specimens were submitted by chest physicians. Conclusions-Often sputum cytology is used inappropriately as a screening investigation on, or soon after, admission. In addition, it is used inappropriately before bronchoscopy. Sputum cytology should be limited to individuals in whom a histological diagnosis is desired, but in whom bronchoscopy is inappropriate or unsuccessful. (i Clin Pathol 1997;50:566-568) Keywords: sputum cytology; sensitivity; cost; specificity; laboratory practice Sputum cytology is a common diagnostic test, forming much of the non-gynaecological cytology workload in many laboratories. Before the development of fibreoptic bronchoscopy, sputum cytology was the only alternative to thoracotomy for tissue diagnosis of many pulmonary neoplasms. It is regarded by clinicians as a simple, cheap, and non-invasive investigation.
Sputum cytology is a common diagnostic test, forming much of the non-gynaecological cytology workload in many laboratories. Before the development of fibreoptic bronchoscopy, sputum cytology was the only alternative to thoracotomy for tissue diagnosis of many pulmonary neoplasms. It is regarded by clinicians as a simple, cheap, and non-invasive investigation.
However, sputum cytology is relatively costly in terms of laboratory time, both during specimen preparation and screening; also, it has a low sensitivity. While there are individuals in whom it is the most appropriate means of investigation, there is an increasing recognition by cytopathologists and chest physicians that in many instances it is not a cost-effective investigation. This study examines the cost of sputum cytology and the laboratory practices of a selection of hospitals in Yorkshire. It also examines the sensitivity and specificity of sputum cytology requests from clinicians in different specialities to delineate better the appropriate role of sputum cytology.
Methods
Five centres participated in the study, ranging from a relatively small district general hospital (350 beds) to a large general hospital with a significant teaching commitment (800 beds), and including one specialist cardiothoracic hospital. The participating pathologists were all consultants with a minimum of four years consultancy experience. All have a sizeable cytology workload, and one has a special interest in cardiothoracic pathology. All sputum cytology requests received from 1 January to 31 December 1993 were analysed with respect to age, sex, clinical details, requesting clinician, and cytology findings. Subsequent investigative procedures and final diagnosis were obtained either from the hospital's clinical information system or from case notes. The number of bronchoscopic examinations undertaken during the same period was also determined. These were categorised according to histological diagnosis on biopsy, and whether there had been previous sputum examination.
The laboratory procedure for examination of sputum cytology was compared for each of the participating hospitals. The cost per request was determined using the costing method outlined by the Audit Commission for "Critical Path", the study of Pathology services in Great Britain.'
Results

LABORATORY PROCEDURES
All five centres followed a similar laboratory protocol. All centres recommend that at least three separate samples are submitted from each individual, in accordance with the literature.2 3 One centre prepared three slides from each sample, the remainder prepared two slides. In all centres, initial screening was by a medical laboratory scientific officer (MLSO) or experienced cytoscreener. In one centre, a consultant "checked out" all specimens, including negative tests. In the remaining four centres, consultants only checked suspicious and positive specimens. The cost per request ranged from £16.83 to £36.78 (mean £26.93). Therefore, a minimum set of three samples would cost an average of £79.17. The major factor influencing cost was laboratory overheads, the laboratory in which all slides were checked by a consultant having the lowest cost.
CYTOLOGY DATA Table 1 shows the number of samples received in each laboratory, the corresponding number of patients, and the cytological diagnosis. Evidently, most centres were not even submitting the three samples recommended as a minimum for reliable diagnosis. Figure 1 Proporti 28% to 58% (mean 36%) (table 2). The specificity was 99.6%.
BRONCHOSCOPY
In each centre, the majority of bronchoscopies was undertaken without prior cytology. Analysis of the subgroup who underwent bronchoscopy and had sputum cytology shows that on average only 20% of individuals proven subsequently to have a bronchial carcinoma had positive sputum cytology, with a further 20% having a borderline or suspicious report (table  3) . Of those with a positive cytological diagnosis before bronchoscopy, the decision to undertake bronchoscopy did not appear to be determined by the cell type of the tumour. Number of specimens biopsy may yield a diagnosis in up to 85% of on ofpositive samples submitted by differing specialities.
cases. 6 The additional cost of sputum cytology Gledhill, Bates, Henderson, DaCosta, Thomas The single most important factor in the low sensitivity demonstrated in this study was the low number of specimens received from each patient, a mean of 1.9 per patient. Sensitivity improves with increasing number of samples, and it has been suggested that a minimum of five samples must be examined to exclude pulmonary cancer with confidence.8'-0 While 95% of patients with bronchial carcinoma will require no more than six samples before malignant cells are seen, 5% will require seven or more repeated specimens.7 The number of slides prepared from each sample may also be significant, but probably less so. It has been recommended that four slides should be prepared from each sample.3 In this series, centres prepared two or three, the highest detection rate being in a centre preparing two slides per sample.
In addition, we believe that poor specimen collection limited the detection rate. Informal inquiries among ward staff suggest that the attention paid to the collection of sputum often is less than ideal, with specimens coming "as and when", and not being early morning deep cough specimens. Previous authors have expressed the extreme importance of the early morning, deep cough specimen. 9 10 We conclude that sputum cytology is being requested inappropriately as part of the routine investigations on admission. Also, it is requested inappropriately as part of the work-up for bronchoscopy. Sputum examination should be limited to individuals with a high clinical suspicion of neoplasia, in whom bronchoscopy is contraindicated or inappropriate. When used, due attention must be paid to specimen collection, and to the collection of multiple specimens. This is the practice already followed by most chest physicians. If practitioners in other areas adopted the same approach, the investigation costs of many patients would be reduced, allowing a more appropriate use of resources. There would also be the benefit that the non-gynaecological workload in many laboratories could be reduced, job satisfaction would increase because of the higher positive detection rate in the remaining work, and the ever present infection risk in handling sputum would be diminished.
